We are live on
!
Find out more
EP
Eversept Partners Portfolio holdings
AUM
$1.93B
Turnover
41.06%
1-Year Est. Return
160.8%
This Fund
S&P 500
This Quarter
Est. Return
-7.76%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.41B
AUM Growth
+$104M
(+8%)
Cap. Flow
+$94.2M
Cap. Flow
% of AUM
6.7%
Top 10 Holdings %
Top 10 Hldgs %
55.6%
Holding
106
New
20
Increased
33
Reduced
17
Closed
29
Avg Time Held Equity + Options
0.9
years
Top 10 Avg Time Held Equity + Options
0.9
years
Top 20 Avg Time Held Equity + Options
1
year
Avg Time Held Equity only
1.1
years
Top 10 Avg Time Held Equity only
0.9
years
Top 20 Avg Time Held Equity only
1.1
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sanofi
SNY
|
+$46.7M |
| 2 |
State Street SPDR S&P Biotech ETF
XBI
|
+$26.7M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$26.5M |
| 4 |
Tandem Diabetes Care
TNDM
|
+$21M |
| 5 |
ABMD
Abiomed Inc
ABMD
|
+$18.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ascendis Pharma A/S
ASND
|
+$49M |
| 2 |
HCA Healthcare
HCA
|
+$27.9M |
| 3 |
Masimo
MASI
|
+$27.2M |
| 4 |
ARK Genomic Revolution ETF
ARKG
|
+$21.6M |
| 5 |
R1 RCM Inc. Common Stock
RCM
|
+$17.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 70.04% |
| 2 | Miscellaneous | 29.08% |
| 3 | Industrials | 0.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
76
Bolt Biotherapeutics
BOLT
$7.65M
| $63.6K | ﹤0.01% |
+1,559
| New | +$60.5K |
2022 Q2
0 quarters
|
|
77
Crescent Biopharma
CBIO
$449M
| $60.1K | ﹤0.01% |
1,006
| – | – |
2021 Q4
2 quarters
|
|
|
ADAP
78
DELISTED
Adaptimmune Therapeutics
ADAP
| – | – |
-237,086
| Closed | -$488K | – |
|
|
79
ARK Genomic Revolution ETF
ARKG
$1.99B
| – | – |
-470,506
| Closed | -$21.6M | – |
|
80
Assembly Biosciences
ASMB
$410M
| – | – |
-23,333
| Closed | -$577K | – |
|
|
81
Ascendis Pharma A/S
ASND
$14.9B
| – | – |
-417,172
| Closed | -$49M | – |
|
82
Autolus Therapeutics
AUTL
$429M
| – | – |
-371,540
| Closed | -$1.55M | – |
|
83
CALL
Biogen
BIIB
$34.6B
| – | – |
-140,000
| Closed | -$29.5M | – |
|
|
KRSA
84
Korsana Biosciences, Inc. Common Stock
KRSA
$1.49B
| – | – |
-2,657
| Closed | -$413K | – |
|
85
The Ensign Group
ENSG
$10.3B
| – | – |
-10,397
| Closed | -$936K | – |
|
86
PUT
iShares MSCI Taiwan ETF
EWT
$11.6B
| – | – |
-100,000
| Closed | -$6.14M | – |
|
87
Exelixis
EXEL
$15.4B
| – | – |
-203,156
| Closed | -$4.61M | – |
|
|
88
HCA Healthcare
HCA
$99.5B
| – | – |
-111,440
| Closed | -$27.9M | – |
|
89
iRhythm Holdings
IRTC
$3.66B
| – | – |
-27,047
| Closed | -$4.26M | – |
|
90
PUT
iShares Russell 2000 Growth ETF
IWO
$13.4B
| – | – |
-1,700
| Closed | -$435K | – |
|
91
Kodiak Sciences
KOD
$5.53B
| – | – |
-91,200
| Closed | -$704K | – |
|
|
92
PUT
Kodiak Sciences
KOD
$5.53B
| – | – |
-181,200
| Closed | -$1.4M | – |
|
93
McKesson
MCK
$117B
| – | – |
-52,375
| Closed | -$16.1M | – |
|
94
Mereo BioPharma
MREO
$47.5M
| – | – |
-370,170
| Closed | -$415K | – |
|
95
Merck
MRK
$363B
| – | – |
-9,483
| Closed | -$841K | – |
|
96
PUT
Progyny
PGNY
$2.08B
| – | – |
-50,000
| Closed | -$2.57M | – |
|
97
Spero Therapeutics
SPRO
$65.2M
| – | – |
-59,639
| Closed | -$519K | – |
|
98
Bio-Techne
TECH
$11.4B
| – | – |
-4,248
| Closed | -$460K | – |
|
99
Tectonic Therapeutic
TECX
$412M
| – | – |
-24,614
| Closed | -$390K | – |
|
100
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| – | – |
-15,934
| Closed | -$2.02M | – |
|
Similar funds
SWM
RIA
SI
SG
DCP
SI
MFM
FWP
Eversept Partners's Q2 2022 Portfolio in Review
As of Q2 2022, Eversept Partners held 106 positions worth $1.41B, up 8% from $1.3B the previous quarter. Its ten largest holdings account for 56% of the portfolio.
Eversept Partners deployed $94.2M of net new capital in Q2 2022, opening 20 new positions and adding to 33 existing holdings. Its largest new stake was Sanofi: 879,460 shares worth $44M.
By sector, the portfolio is most concentrated in Healthcare at 70% of assets, down from 79% a quarter earlier, followed by Miscellaneous and Industrials.
On the sell side, the largest reduction was Masimo, an estimated $27.2M trimmed.
- Eversept Partners's largest Q2 2022 buy was Sanofi: 879,460 shares worth $44M.
- Eversept Partners added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2022, an estimated $26.5M increase.
- Eversept Partners's biggest Q2 2022 reduction was Masimo, cutting an estimated $27.2M.
- Eversept Partners fully exited Ascendis Pharma A/S in Q2 2022, selling an estimated $49M.
- Eversept Partners's ten largest holdings make up 56% of its $1.41B portfolio in Q2 2022.
- Eversept Partners opened 20 new positions and closed 29 in Q2 2022.
- Eversept Partners's portfolio value rose 8% quarter-over-quarter to $1.41B.
Based on Eversept Partners's 13F filing for Q2 2022, filed 15 Aug 2022.